Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.60 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL4437676 | 0.91 | ROCK2 (0.54) | KCNH2BIRC5ROCK2PIM1PIM3 | |
| SCHEMBL6593806 | 0.86 | AHR (0.54) | KCNH2BIRC5CYP19A1 | |
| SCHEMBL5659440 | 0.86 | BIRC5 (0.54) | KCNH2BIRC5CYP19A1 | |
| SCHEMBL4557834 | 0.82 | BIRC5 (0.62) | KCNH2BIRC5CYP19A1ROCK2PIM1 | |
| SCHEMBL4296315 | 0.79 | KCNH2 (0.60) | KCNH2BIRC5 | |
| SCHEMBL4572982 | 0.79 | KCNH2 (0.60) | KCNH2BIRC5 | |
| SCHEMBL9463558 | 0.79 | KCNH2 (0.65) | KCNH2BIRC5CYP19A1 | |
| SCHEMBL5735272 | 0.79 | KCNH2 (0.60) | KCNH2BIRC5 | |
| SCHEMBL22204996 | 0.79 | KCNH2 (0.60) | KCNH2BIRC5 | |
| SCHEMBL31165290 | 0.79 | KCNH2 (0.60) | KCNH2BIRC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109433267-B | Preparation method of sertindole intermediate for resisting delayed dyskinesia | 河南立诺制药有限公司 | 2021-11-23 | — | — | CN | claimed |
| US-20090264656-A1 | METHOD FOR MANUFACTURE OF SERTINDOLE | H. LUNDBECK A/S (DK) | 2009-10-22 | — | — | US | claimed |
| CN-100528863-C | Method for manufacture of sertindole | LUNDBECK & CO AS H (DK) | 2009-08-19 | — | — | CN | claimed |
| EP-1661887-A1 | Method for manufacture of sertindole | H.Lundbeck A/S (DK) | 2006-05-31 | — | — | EP | claimed |
| CN-1243001-C | Process for the manufacture of sertindole | LUNDBECK & CO AS H (DK) | 2006-02-22 | — | — | CN | claimed |
| CN-1642942-A | Method for manufacture of sertindole | LUNDBECK & CO AS H (DK) | 2005-07-20 | — | — | CN | claimed |
| US-20050101788-A1 | Method for manufacture of sertindole | H. LUNDBECK A/S (DK) | 2005-05-12 | — | — | US | claimed |
| EP-1260511-B1 | Process for the preparation of 5-chloro-1-(4-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)indole and method of manufacturing sertindole | LUNDBECK & CO AS H (DK) | 2004-12-29 | — | — | EP | claimed |
| EP-0983264-B1 | METHOD OF MANUFACTURING SERTINDOLE | LUNDBECK & CO AS H (DK) | 2004-02-04 | — | — | EP | claimed |
| EP-1260511-A1 | Process for the preparation of 5-chloro-1-(4-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)indole and method of manufacturing sertindole | H. Lundbeck A/S (DK) | 2002-11-27 | — | — | EP | claimed |
| US-6335463-B1 | Method of manufacturing sertindole | H. LUNDBECK A/S (DK) | 2002-01-01 | — | — | US | claimed |
| CN-1261363-A | Process for the manufacture of sertindole | LUNDBECK & CO AS H (DK) | 2000-07-26 | — | — | CN | claimed |
| EP-0983264-A1 | METHOD OF MANUFACTURING SERTINDOLE | H. LUNDBECK A/S (DK) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051685-A1 | METHOD OF MANUFACTURING SERTINDOLE | H. LUNDBECK A/S (DK) | 1998-11-19 | — | — | WO | claimed |
| CN-109433267-B | Preparation method of sertindole intermediate for resisting delayed dyskinesia | 河南立诺制药有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-109433267-B | Preparation method of sertindole intermediate for resisting delayed dyskinesia | 河南立诺制药有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-109433267-A | A kind of preparation method of anti-tardive dyskinesia sertindole drug intermediate | 泰山医学院 | 2019-03-08 | — | — | CN | disclosed |
| CN-1142824-A | 3-substituted 1-arylindole compounds | LUNDBECK & CO AS H (DK) | 1997-02-12 | — | — | CN | disclosed |
| EP-0734384-A1 | 3-SUBSTITUTED 1-ARYLINDOLE COMPOUNDS | H. LUNDBECK A/S (DK) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995016684-A1 | 3-SUBSTITUTED 1-ARYLINDOLE COMPOUNDS | H. LUNDBECK A/S (DK) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101788-A1 | Method for manufacture of sertindole | HTR3C, TPH1, SLC6A4 | KCNH2 776/4885BIRC5 2764/4885CYP19A1 670/4885 |
| US-20090264656-A1 | METHOD FOR MANUFACTURE OF SERTINDOLE | HTR3C, TPH1, SLC6A4 | KCNH2 765/4885BIRC5 2730/4885CYP19A1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.